Acrivon Therapeutics, Inc. (ACRV): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Acrivon Therapeutics, Inc. (ACRV) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 acrv-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 Acrivon Therapeutics, Inc. Amended and Restated 2022 Equity Incentive Plan Adopted by the Board of Directors: May 20, 2026 Approved by the Stockholders: June 17, 2026 1. General. (a) Successor to and Continuation of Prior Pla
How this was made
The 30-second read
Why it matters
The key tradable element is the plan’s share reserve capacity (up to 8,606,723 shares plus potential annual 5% refresh for ten years), which can influence dilution expectations if/when awards are granted.
Market read
This is a compensation-plan mechanics disclosure; it may slightly shift dilution/valuation expectations but lacks immediate financial or operational catalysts.
What to watch
Traders may focus on the absence of any disclosed director/officer changes details beyond plan adoption, which reduces immediate catalyst strength.
Background
The company’s 8-K includes Item 5.02/5.07 and an Exhibit 10.1 describing an amended and restated equity incentive plan adopted by the board and approved by stockholders on June 17, 2026.
Ticker impact
Acrivon Therapeutics filed an 8-K adopting an amended and restated 2022 Equity Incentive Plan with a new share reserve and annual 5% refresh.
Likely limited near-term impact; any effect would come through expectations for future equity issuance rather than immediate fundamentals.
The filing is primarily governance/compensation-plan mechanics (share reserve, award types, refresh provisions) without disclosed grant sizes or financial guidance.
Market effects
Routine biotech compensation-plan refreshes can modestly affect dilution expectations across small-cap life sciences.
None specific beyond US small-cap sentiment.
None specific.
Counterpoint
The plan’s 5% annual share refresh may be largely formulaic; without disclosed grant amounts, dilution risk may be overstated by traders.
Key entities
- companyAcrivon Therapeutics, Inc.
Subject of the SEC 8-K; adopted an amended and restated 2022 Equity Incentive Plan with a defined share reserve and annual refresh mechanics.
- documentAmended and Restated 2022 Equity Incentive Plan
Exhibit 10.1 outlining award types, share reserve limits, and an automatic annual increase of 5% of fully diluted shares for ten years.
